Global Fludarabine Phosphate Injection Market Insights, Forecast to 2028

Fludarabine Phosphate Injection contains fludarabine phosphate, a nucleotide metabolic inhibitor. Fludarabine phosphate is a fluorinated nucleotide analog of the antiviral agent vidarabine, 9-β-Darabinofuranosyladenine (ara-A), that is relatively resistant to deamination by adenosine deaminase. Fludarabine Phosphate Injection is indicated for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen.
Market Analysis and Insights: Global Fludarabine Phosphate Injection Market
Due to the COVID-19 pandemic, the global Fludarabine Phosphate Injection market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, 50mg/6mL accounting for % of the Fludarabine Phosphate Injection global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Adult Use segment is altered to an % CAGR throughout this forecast period.
China Fludarabine Phosphate Injection market size is valued at US$ million in 2021, while the US and Europe Fludarabine Phosphate Injection are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Fludarabine Phosphate Injection landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Fludarabine Phosphate Injection include Leucadia Pharmaceuticals, Actavis, Accord Healthcare, SAGENT Pharmaceuticals, Fresenius Kabi, Mylan Inc, Pfizer, Cisen Pharmaceutical and Actiza Pharmaceutical, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Fludarabine Phosphate Injection Scope and Segment
Fludarabine Phosphate Injection market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Fludarabine Phosphate Injection market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.

Segment by Type
50mg/6mL
50mg/2mL

Segment by Application
Adult Use
Pediatric Use

By Company
Leucadia Pharmaceuticals
Actavis
Accord Healthcare
SAGENT Pharmaceuticals
Fresenius Kabi
Mylan Inc
Pfizer
Cisen Pharmaceutical
Actiza Pharmaceutical
United Biotech
Therdose Pharma

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE